## §SELF — miscsubjects portable reference **Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next. **This widget:** `article_bundle` — **LLM article bundle** Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. - **article slug:** `vip-ppis` - **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest - **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system. - **read:** https://miscsubjects.com/api/articles/vip-ppis/bundle?format=markdown ### Logical proof (verify each step) 1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution 2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/vip-ppis/sources 3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol 4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow 5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex 6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map ### Related features (explains other parts of the system) - **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/vip-ppis/topology - **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/vip-ppis/voxels - **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/vip-ppis/prompts - **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node. - **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/vip-ppis/voxels - **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest ### Full index - JSON: https://miscsubjects.com/api/articles/system-map - Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown ### §STRUCTURE This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure ### §INTEGRITY Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you. ### §GAUNTLET Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted. *Not medical advice. Tier-honest. Cite claim/source ids.* --- # miscsubjects article bundle > Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest. ## MASTHEAD - **identity:** `vip-ppis` v2 · content_hash `64df5f98b9b083b6…` · thread_head genesis · 27 DIVs - **thesis (c1):** PPIs such as omeprazole and lansoprazole increase plasma VIP levels in humans - c5 [human/active] No human trials test VIP supplementation against PPI side effects - c2 [preclinical/active] PPIs link to higher intestinal permeability through mast cell-VIP axis in stressed models - c4 [preclinical/active] VIP can inhibit gastric acid secretion in physiological studies - c3 [mechanistic/active] VIP participates in smooth muscle relaxation, fluid secretion, and barrier modulation - **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes - **standing objections:** 0 open → https://miscsubjects.com/api/articles/vip-ppis/discourse - **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key - **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/vip-ppis/discourse · https://miscsubjects.com/api/protocol ## Article - **slug:** `vip-ppis` - **title:** VIP for PPIs: Evidence on Vasoactive Intestinal Peptide and Proton Pump Inhibitors - **url:** https://miscsubjects.com/a/vip-ppis - **register:** source_ledger - **updated:** 2026-07-17T02:43:26.778Z - **tags:** peptide, matrix ## Body ## What's breaking down if you have PPIs (omeprazole, etc.) Long-term proton pump inhibitor use suppresses stomach acid production. This reduces symptoms of acid-related issues but alters gut peptide balance. Studies show PPIs such as omeprazole and lansoprazole increase plasma VIP levels in humans (source s1, s2). Other layers include changes in intestinal permeability. One line of research links PPIs to higher permeability through a mast cell and VIP pathway in stressed models (source s3). Nutrient absorption can shift over months or years. Rebound acid hypersecretion often follows stopping the drug. These effects sit in the category of suppression of a signal rather than direct support for ongoing mucosal repair pathways. ## Why VIP might help you You are reading about **PPIs (omeprazole, etc.)** — what breaks down matters before any compound name. **Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain. VIP acts on immune and autonomic layers in the gut. It participates in smooth muscle relaxation, fluid secretion, and barrier modulation in physiological studies. If PPI-driven permeability changes involve VIP signaling, exogenous VIP could intersect with those autonomic and immune routes. No human trial tests VIP supplementation against PPI side effects, so this remains a mechanistic connection drawn from known peptide actions and observed PPI effects on VIP levels. ## Why PPIs (omeprazole, etc.) matters for you **Drug:** PPIs (omeprazole, etc.) **What it does:** Acid suppression; long-term mucosal and nutrient consequences. **Therefore for you:** This drug suppresses a signal (acid output). It can reduce immediate tissue stress from excess acid but trades off against full repair cycles by changing peptide profiles and permeability. The acid reduction helps symptom control yet leaves downstream autonomic and mucosal layers altered, which is why repair-focused compounds like VIP enter the conversation. ## How these fit together Single-compound focus — VIP targets the immune / autonomic layer. PPIs suppress acid while raising endogenous VIP. The combination points to a possible feedback where the drug alters the very peptide under study. VIP's tissue-level actions on barrier function and motility sit alongside the drug's suppression effects without overlapping on acid production itself. ## What the evidence actually shows Human data: Two small studies measured plasma peptides after PPI dosing. Omeprazole raised somatostatin, motilin, and VIP in healthy volunteers (source s2). Lansoprazole raised somatostatin, CGRP, substance P, and was noted to increase VIP in another report (source s1). These are short-term observations in plasma, not clinical outcomes. Preclinical data: Animal work shows VIP can inhibit gastric acid secretion and support intestinal barrier integrity in infection models (source s4). A mouse study linked PPI effects on permeability to VIP receptor pathways (source s3). VIP physiology reviews confirm its roles in gut secretion and relaxation across species (source s5). Anecdotal: No substantial Reddit or X discussions appear in targeted searches tying VIP peptide use to PPI contexts. ## What scientists say Reviews describe VIP as a gut neuropeptide with vasodilatory, secretory, and immunomodulatory actions. It inhibits acid secretion in isolated tissue and whole-animal preparations. Researchers note PPIs elevate circulating VIP, suggesting a compensatory or off-target response. No clinical guidelines mention VIP as an adjunct or countermeasure for PPI users. ## What people say on Reddit Searches across relevant subreddits returned no direct user reports on VIP peptide use alongside PPIs. Discussions on long-term PPI effects focus on nutrient testing and deprescribing rather than peptide interventions. ## What people say on X Targeted searches yielded no relevant posts connecting VIP peptide to PPI experience or evidence. General peptide conversation exists but does not address this specific cross. ## What we do not know No randomized human trials test VIP administration in people taking PPIs. Duration, dosing routes, and safety of exogenous VIP remain unstudied in this population. Whether elevated endogenous VIP from PPIs produces net benefit or drawback at the tissue level is unclear. Long-term outcomes on permeability, microbiome, or nutrient status after VIP exposure are unknown. ## Safety and limits VIP is an endogenous peptide with established physiological roles. Any external use carries the standard uncertainties of research compounds: purity, stability, and individual response variation. Human safety data for supplemental VIP in the context of acid suppression drugs do not exist. Readers should consult primary literature and clinicians for personal decisions. All information here is for evidence-mapping purposes only. ## Claims (5) - **c1** [human w=0.8] PPIs such as omeprazole and lansoprazole increase plasma VIP levels in humans - who_claims: grok/grok-4.3 - sources: s1, s2 - **c5** [human w=0.8] No human trials test VIP supplementation against PPI side effects - who_claims: grok/grok-4.3 - **c2** [preclinical w=0.5] PPIs link to higher intestinal permeability through mast cell-VIP axis in stressed models - who_claims: grok/grok-4.3 - sources: s3 - **c4** [preclinical w=0.5] VIP can inhibit gastric acid secretion in physiological studies - who_claims: grok/grok-4.3 - sources: s5 - **c3** [mechanistic w=0.3] VIP participates in smooth muscle relaxation, fluid secretion, and barrier modulation - who_claims: grok/grok-4.3 - sources: s5 ## Voxel graph (5 atoms · 10 edges) - full graph: https://miscsubjects.com/api/articles/vip-ppis/voxels ## Article constitution - full: https://miscsubjects.com/api/articles/constitution ## Source ledger (5) - chain valid: yes · head: `ea30227eec15fee4` ### s1 · pubmed · http_403 - title: Lansoprazole Raises Somatostatin, Calcitonin Gene-Related Peptide and Substance P Levels in Healthy Human Plasma - url: https://www.researchgate.net/publication/246500942_Lansoprazole_Raises_Somatostatin_Calcitonin_Gene-Related_Peptide_and_Substance_P_Levels_in_Healthy_Human_Plasma - summary: Notes PPI effect on VIP in human plasma context - quote: Proton pump inhibitors (PPIs) are known to increase levels of vasoactive intestinal peptide (VIP) - claim_ids: c1 - hash: `ba90e018a091243e` ### s2 · pubmed · ok - title: Omeprazole Raises Somatostatin and Motilin in Human Plasma - url: https://bpb.pharm.or.jp/abst/200502/ab28020370.html - summary: Documents omeprazole raising VIP and related peptides in humans - quote: we examined the effects of omeprazole on the levels of gastrointestinal peptides (somatostatin, motilin, gastrin, vasoactive intestinal peptide (VIP) - claim_ids: c1 - hash: `bc0d8439ee30c3e2` ### s3 · pubmed · ok - title: Proton pump inhibitors enhance intestinal permeability via mast cell-VIP axis - url: https://onlinelibrary.wiley.com/doi/10.1111/nmo.13841 - summary: Preclinical link between PPIs, permeability, and VIP pathway - quote: Moreover, both vasoactive intestinal peptide (VIP) receptor antagonist and ketotifen significantly reversed the effect of PPI on intestinal permeability - claim_ids: c2 - hash: `1bff643684befe1a` ### s5 · review · ok - title: Recent advances in vasoactive intestinal peptide physiology - url: https://pmc.ncbi.nlm.nih.gov/articles/PMC6743256/ - summary: Comprehensive review of VIP gut actions including acid inhibition - quote: Vasoactive intestinal peptide (VIP), a gut peptide hormone originally reported as a vasodilator in 1970, has multiple physiological and pathological effects. - claim_ids: c3, c4 - hash: `ea30227eec15fee4` ### s4 · pubmed · ok - title: Vasoactive intestinal peptide ameliorates intestinal barrier dysfunction - url: https://pubmed.ncbi.nlm.nih.gov/19661153/ - summary: Animal model showing VIP support for barrier function - quote: The aim of this study was to examine whether VIP treatment modulated Citrobacter rodentium-induced disruption of intestinal barrier integrity - hash: `77fa95a540d6c202` ## Provenance (2 model passes) - chain valid: yes · head: `c97509ef428eb27b` - write · grok/grok-4.3 · 2026-06-29T22:21 · hash `57f264b98ac2` - voxel_divide · owner · 2026-07-17T02:43 · hash `c97509ef428e` ## Question graph - questions: 0 · evidence ingests: 0 ## LLM manifest — how to communicate with this ledger - system map: https://miscsubjects.com/api/articles/system-map?format=markdown - topology (ranked): https://miscsubjects.com/api/articles/vip-ppis/topology - ingest: POST https://miscsubjects.com/api/protocol/ingest - claim: POST https://miscsubjects.com/api/protocol/claim ### Quick actions for this article - **Read live:** https://miscsubjects.com/api/articles/vip-ppis/topology - **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"vip-ppis","question":"..."}` - **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest vip-ppis|your evidence` - **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim vip-ppis|tier|assertion` - **iMessage ask:** `vip-ppis|your question` - **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown --- ## §SELF — miscsubjects portable reference **Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next. **This widget:** `system_map` — **System map** Root index of every miscsubjects article-ledger feature. Start here if you have zero context. - **article slug:** `vip-ppis` - **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest - **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context. - **read:** https://miscsubjects.com/api/articles/system-map ### Logical proof (verify each step) 1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution 2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/vip-ppis/sources 3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol 4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow 5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex 6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map ### Related features (explains other parts of the system) - **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution - **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest - **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip - **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip - **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/vip-ppis/bundle?format=markdown - **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown ### Full index - JSON: https://miscsubjects.com/api/articles/system-map - Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown ### §STRUCTURE This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure ### §INTEGRITY Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you. ### §GAUNTLET Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted. *Not medical advice. Tier-honest. Cite claim/source ids.*